Development and characterization of a glucagon-like peptide 1-albumin conjugate the ability to activate the glucagon-like peptide 1 receptor in vivo

Diabetes

Volumn 52, Issue 3, 2003, Pages 751-759

  Kim, Jung Guk ^a   Baggio, Laurie L ^a   Bridon, Dominique P ^b   Castaigne, Jean Paul ^b   Robitaille, Martin F ^b   Jetté, Lucie ^b   Benquet, Corinne ^b   Drucker, Daniel J ^a,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b Conjuchem ^*  (Canada)

^c MBRW 4R 402 ^*  (Canada)

Author keywords

AUC, area under the curve; CHO, Chinese hamster ovary; DAC, drug affinity complex; DPP IV, dipeptidyl peptidase IV; GIP, glucose dependent insulinotropic peptide; GLP 1, glucagon like peptide 1; GLP 1R, GLP 1 receptor; HSA, human serum albumin

Indexed keywords

ALBUMIN CONJUGATE; BROXURIDINE; CJC 1131; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE; MESSENGER RNA; PROINSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; FIBROBLAST; GLUCOSE METABOLISM; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; CHO CELLS; CRICETINAE; CYCLIC AMP; DIABETES MELLITUS; FIBROBLASTS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MALEIMIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PEPTIDES; PROINSULIN; PROTEIN PRECURSORS; RECEPTORS, GLUCAGON; RECOMBINANT PROTEINS; RNA, MESSENGER; SERUM ALBUMIN; TRANSFECTION;

EID: 0037339649     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.3.751     Document Type: Article

References (48)

1. Drucker DJ: The glucagon-like peptides. Diabetes 47:159-169, 1998
2. Holst JJ: Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10:229-235 1999
3. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
4. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
5. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
6. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Egan JM, Bonner-Weir S, Habener JF: Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 49:741-748, 2000
7. Dupre J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828, 1973
8. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50:1004-1011, 2001
9. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitor polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
10. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
11. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and non-diabetic subjects. Diabetes Care 15:270-276, 1992
12. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
13. Drucker DJ: Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 7:1399-1412, 2001
14. Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304, 1987
15. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
16. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
17. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
18. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 284:501-506, 2001
19. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97:6874-6879, 2000
20. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331, 1999
21. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258, 1998
22. Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48:385-389, 1999
23. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875, 2002
24. Drucker DJ: Biological actions and therapeutic potential of the glucagonlike peptides. Gastroenterology 122:531-544, 2002
25. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034, 1999
26. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-161, 2001
27. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nature Med 2:1254-1258, 1996
28. Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, Drucker DJ: Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biot Chem 274:30459-30467, 1999
29. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ: Sustained expression of exendin-4 does not perturb glucose homeostasis, β cell mass or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 275:2000
30. White SA, Hughes DP, Contractor HH, London NJ: A comparison of cross sectional surface area densities between adult and juvenile porcine islets of Langerhans. Horm Metab Res 31:519-524, 1999
31. Scrocchi LA, Hill ME, Saleh J, Perkins B, Drucker DJ: Elimination of GLP-1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 49:1552-1560, 2000
32. Chuang VT, Kragh-Hansen U, Otagiri M: Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19:569-577, 2002
33. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035-35043, 2002
34. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434-3438, 1987
35. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC: Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382-387, 2001
36. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143, 1999
37. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetelogia 45:195-202, 2002
38. Goke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655,1993
39. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290, 2002
40. Peters T Jr: Serum albumin. Adv Protein Chem 37:161-245, 1985
41. Koehler M, Zobel K, Beresmi M, Caris L, Combs D, Paasch B, Lazarus R: Albumin affinity tags increase peptide half-life in vivo. Bioorg Med Chem Lett 12:2883, 2002
42. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J: Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312(Pt 3):725-731, 1995
43. Hui H, Farilla L, Merkel P, Perfetti R: The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 146:863-869, 2002
44. Wang Q, Brubaker PL: Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263-1273, 2002
45. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB: The long acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283:E745-752, 2002
46. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530-2539, 2001
47. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50, 1999
48. Kvietys PR, Perry MA, Granger DN: Permeability of pancreatic capillaries to small molecules. Am J Physiol 245:G519-524, 1983